Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

66°
- Newport, VT (05855)
  Today
  
  Showers tapering off early with foggy conditions overnight. Areas of patchy fog. Low around 55F. Winds light and variable. Chance of rain 90%..
  
  Tonight
  
  Showers tapering off early with foggy conditions overnight. Areas of patchy fog. Low around 55F. Winds light and variable. Chance of rain 90%.
  
  Updated: September 17, 2026 @ 6:15 pm
- Full Forecast

Site search

Home
News
Sports
Entertainment
- Calendar
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
- Place an ad
Archives
Best of 2025

Recent Quotes

View Full List

My Watchlist

A.P Moller-Mrs ADR

Accolade, Inc. - common stock

AdvanSix Inc. Common Stock

Allegion Plc

Allianz Se ADR

Astra Space, Inc. - Class A Common Stock

BOA Acquisition Corp. II - Units

Banyan Gold Corp

Bolt Projects Holdings, Inc. - Common Stock

California BanCorp - Common Stock

ChoiceOne Financial Services, Inc. - Common Stock

Coliseum Acquisition Corp. - Class A Ordinary Share

Cuprina Holdings (Cayman) Limited - Class A Ordinary shares

DMC Global Inc. - Common Stock

Dicerna Pharmaceuticals, Inc. - Common Stock

Evofem Biosciences, Inc. - Common Stock

Exro Technologies Inc

F-star Therapeutics, Inc. - Common Stock

FitLife Brands, Inc. - Common Stock

Fujitsu Ltd ADR

Global Self Storage, Inc. - Common Stock

Granite Creek Copper Ltd

HeartSciences Inc. - Warrant

Herman Miller Inc

IBEX Limited - Common Share

International Land Alliance Inc

LTC Properties, Inc. Common Stock

LanzaTech Global, Inc. - Warrant

Legence Corp. - Class A Common stock

LightPath Technologies, Inc. - Class A Common Stock

Liminatus Pharma, Inc. - Class A Common Stock

Linkage Global Inc - Class A Ordinary Shares

Logan Ridge Finance Corporation - Common Stock

MICT, Inc. - Common Stock

MSP Recovery, Inc. - Class A Common Stock

Magellan Midstream Partners L.P. Limited Partnership

Magic Empire Global Limited - Class A Ordinary Shares

Marin Software Incorporated - Common Stock

Marpai, Inc. - Class A Common Stock

MaxCyte, Inc. - Common Stock

Mechanics Bancorp - Class A Common Stock

Mobiv Acquisition Corp - Class A Common Stock

Mountain Valley MD Holdings Inc

MultiSensor AI Holdings, Inc. - Common Stock

My Size, Inc. - Common Stock

Noble Roman's Inc

PIMCO Municipal Income Fund Common Stock

Penn Virginia Corporation - Common Stock

Perma-Pipe International Holdings, Inc. - Common Stock

Phunware, Inc. - Common Stock

Playboy, Inc. - Common Stock

PolyOne Corporation Common Stock

Premier Financial Bancorp, Inc. - Common Stock

Princeton Bancorp, Inc. - Common Stock

Sierra Wireless, Inc. - Common Stock

Singularity Future Technology Ltd. - Common Stock

Slack Technologies, Inc. Class A Common Stock

Sokoman Iron Corp

Sow Good Inc. - Common Stock

Spartan Acquisition Corp II Cl A

Springview Holdings Ltd - Ordinary shares

Spruce Power Holding Corporation Class A Common Stock

Telos Corporation - Common Stock

Tortoise Pipeline & Energy Fund, Inc. Common Stock

TransGlobe Energy Corporation - Common Shares

Treasure Global Inc. - Common Stock

Vital Energy, Inc. Common Stock, par value $0.01 per share

Vor Biopharma Inc. - Common Stock

Waters Corp

Wesco Aircraft Holdings, Inc. Common Stock

XOMA Royalty Corporation - Common Stock

iShares Global Timber & Forestry ETF

Edit Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

250.16 -1.11 (-0.44%)

Delayed Quote Updated: 11:31 AM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup ↗

September 14, 2026

Via Chartmill

Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors ↗

September 09, 2026

Via Chartmill

Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen ↗

September 01, 2026

Via Chartmill

If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today ↗

August 26, 2026

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market...

Via Benzinga

Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Revenue surged 105% year-over-year as three approved products scale globally.

Via The Motley Fool

Topics Earnings

Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup ↗

August 11, 2026

Via Chartmill

Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup ↗

July 20, 2026

Via Chartmill

ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗

May 18, 2026

Via Chartmill

Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗

February 11, 2026

Via Chartmill

Topics Earnings

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

August 18, 2026

From Eyconis Inc.

Via GlobeNewswire

Ascendis Pharma A/S Q2 Earnings Call Highlights ↗

August 13, 2026

Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based...

Via MarketBeat

Topics Earnings

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today ↗

August 11, 2026

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market...

Via Benzinga

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗

January 28, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗

May 09, 2026

The Kayne Anderson Energy Infrastructure Fund targets U.S. energy infrastructure, emphasizing income from MLPs and related equities.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Ascendis (ASND) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗

March 20, 2026

This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Ascendis (ASND) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗

February 11, 2026

Ascendis Pharma (ASND) Q4 2025 Earnings Transcript

Via The Motley Fool

Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗

December 25, 2025

Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%.

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

Ascendis (ASND) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

November 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Obituaries
Local Events
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather
California Privacy Notice

Newport Daily Express

NewportVermontDailyExpress.com
178 Hill Street
Newport, VT 05855
Phone: 802-334-6568
Email: editor@newportvermontdailyexpress.com

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Consent Preferences

Newport, VT (05855)

Today

Tonight

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

All News about Ascendis Pharma A/S - Ordinary Share

Sections

Services

Newport Daily Express